Neurocrine Biosciences (NBIX) Raised to “Hold” at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX) from a sell rating to a hold rating in a research report released on Thursday.

A number of other equities research analysts also recently commented on the stock. Oppenheimer lifted their target price on shares of Neurocrine Biosciences from $105.00 to $110.00 and gave the stock an outperform rating in a research report on Wednesday. ValuEngine downgraded shares of Neurocrine Biosciences from a buy rating to a hold rating in a research report on Friday, February 22nd. Zacks Investment Research downgraded shares of Neurocrine Biosciences from a buy rating to a hold rating in a research report on Saturday, February 9th. Bank of America cut their target price on shares of Neurocrine Biosciences from $124.00 to $117.00 and set a buy rating for the company in a research report on Wednesday, February 6th. Finally, Cantor Fitzgerald reaffirmed an overweight rating on shares of Neurocrine Biosciences in a research report on Wednesday, February 6th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $102.56.

NASDAQ:NBIX opened at $84.39 on Thursday. The company has a quick ratio of 8.24, a current ratio of 8.36 and a debt-to-equity ratio of 0.81. Neurocrine Biosciences has a 12 month low of $64.72 and a 12 month high of $126.98. The company has a market capitalization of $7.60 billion, a price-to-earnings ratio of 383.59, a P/E/G ratio of 29.63 and a beta of 1.86.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, February 5th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.05. Neurocrine Biosciences had a net margin of 4.68% and a return on equity of 5.06%. The business had revenue of $131.49 million during the quarter, compared to the consensus estimate of $132.32 million. During the same quarter in the previous year, the firm posted $0.07 EPS. The firm’s revenue was up 39.1% on a year-over-year basis. On average, sell-side analysts forecast that Neurocrine Biosciences will post 0.11 earnings per share for the current year.

In other news, insider Eiry Roberts sold 1,857 shares of the business’s stock in a transaction on Tuesday, January 8th. The shares were sold at an average price of $84.09, for a total transaction of $156,155.13. Following the completion of the sale, the insider now owns 3,143 shares of the company’s stock, valued at approximately $264,294.87. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Kyle Gano sold 3,809 shares of the business’s stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $88.12, for a total transaction of $335,649.08. Following the sale, the insider now directly owns 17,595 shares of the company’s stock, valued at approximately $1,550,471.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,280 shares of company stock valued at $1,163,054. Insiders own 4.30% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC bought a new position in Neurocrine Biosciences in the 4th quarter worth $32,000. Exane Derivatives boosted its holdings in Neurocrine Biosciences by 48,400.0% in the 4th quarter. Exane Derivatives now owns 485 shares of the company’s stock worth $35,000 after buying an additional 484 shares during the period. Rehmann Capital Advisory Group boosted its holdings in Neurocrine Biosciences by 54.7% in the 3rd quarter. Rehmann Capital Advisory Group now owns 557 shares of the company’s stock worth $68,000 after buying an additional 197 shares during the period. Penserra Capital Management LLC bought a new position in Neurocrine Biosciences in the 4th quarter worth $86,000. Finally, Arbor Wealth Management LLC bought a new position in Neurocrine Biosciences in the 4th quarter worth $92,000.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Recommended Story: Why is cost of goods sold important?

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply